BERKELEY, Calif., Dec. 11, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd.
(Nasdaq:XOMA stock), a leader in the discovery and development of antibody
therapeutics, announced today the addition of John Varian...
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
BERKELEY, Calif.--(BUSINESS WIRE)--XOMA Ltd. (Nasdaq:XOMA) today announced that it has received
final acceptance from the National Institute of Allergy and Infectious
Diseases...
Is XOMA on to something that will result in big things for investors? I think so, and here’s why. A few years a go 60 minutes featured a scientist that had a cure for cancer. And what we saw was...
BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 7, 2006--XOMA Ltd. (Nasdaq:XOMA) today announced successful results with a research formulation of XOMA 629 (formerly XMP.629). XOMA has initiated a...
BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--XOMA Ltd (Nasdaq:XOMA) announced today that the European Commission has granted an orphan medicinal product designation to XOMA's drug NEUPREX(R)...
#27: XOMA News XOMA Unveils Strategy, Provides Update on NEUPREX(R); European Effort Advances Toward Orphan Drug Designation and Approval Under Exceptional Circumstances; US Trials Progress
BERKELEY, Calif.--(BUSINESS WIRE)--Aug. 15, 2006--XOMA Ltd. (Nasdaq:XOMA) today unveiled its strategy and provided an update on the status of its efforts to advance NEUPREX(R) (opebacan) toward...
BERKELEY, Calif.--(BUSINESS WIRE)--Aug. 9, 2006--XOMA Ltd. (NASDAQ:XOMA), a leader in the discovery and development of antibody therapeutics for cancer and immunological disorders, today announced...
#25: XOMA News XOMA Awarded New $16 Million BioDefense Contract with NIAID; Contracts Now Total $31 Million for XOMA to Produce Anti-Botulism Antibodies to Support Human Clinical Trials
BERKELEY, Calif.--(BUSINESS WIRE)--July 31, 2006--XOMA Ltd. (Nasdaq:XOMA) today announced that it has been awarded an exclusive $16 million contract from the National Institute of Allergy and...
BERKELEY, Calif.--(BUSINESS WIRE)--July 28, 2006--XOMA Ltd. (Nasdaq:XOMA) announced today that David Boyle, XOMA's Chief Financial Officer, and Dr. Robert Gundel, XOMA's Vice President for...
BERKELEY, Calif.--(BUSINESS WIRE)--July 28, 2006--XOMA Ltd. (Nasdaq:XOMA) will issue a news release announcing its second quarter financial results for the quarter ended June 30, 2006, on...
BERKELEY, Calif.--(BUSINESS WIRE)--July 28, 2006--XOMA Ltd. (Nasdaq:XOMA) today announced that, in light of Cubist Pharmaceuticals, Inc.'s (Nasdaq:CBST) recently announced decision to cease...
#21: XOMA News XOMA to Receive New Royalty Stream From Bacterial Production License; LUCENTIS(TM) is First Approved Drug Licensed Under XOMA's BCE Program
BERKELEY, Calif.--(BUSINESS WIRE)--July 12, 2006--XOMA Ltd. (Nasdaq:XOMA) today announced that LUCENTIS(TM), owned by Genentech, Inc. (NYSE:DNA) and recently approved by the FDA for the treatment...
BERKELEY, Calif.--(BUSINESS WIRE)--July 11, 2006--XOMA Ltd. (Nasdaq:XOMA) today announced an expansion of its effort to discover, develop and manufacture therapeutic antibodies and other proteins...
